Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Balmer

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Vaccines|April 27, 2026
Immunogenicity and Safety of Extended Dosing Intervals for Pfizer Pentavalent MenABCWY Meningococcal Vaccination in Healthy Adolescents: Results from a Randomized, Phase 2b StudyJake C Jones, Mary D Tipton, Lefteris Zolotas, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 2, 2007
Chemokine responses are increased in HIV-infected Malawian children with invasive pneumococcal diseaseEnitan D Carrol, Limangeni A Mankhambo, Paul Balmer, et al.
Infectious Diseases and Therapy|January 30, 2025
A Phase 3B, Open-Label Study to Evaluate the Immunogenicity and Safety of the Quadrivalent Meningococcal Nimenrix<sup>®</sup> Vaccine When Given to Healthy Infants at 3 and 12 Months of AgeSusanna Koski, Federico Martinon-Torres, Mika Rämet, et al.
The Lancet. Infectious Diseases|August 14, 2023
Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trialJames Peterson, Daniel Drazan, Hanna Czajka, et al.
Critical Care (London, England)|May 25, 2010
The role of angiogenic factors in predicting clinical outcome in severe bacterial infection in Malawian childrenLimangeni A Mankhambo, Daniel L Banda, , et al.
Expert Review of Vaccines|June 9, 2018
From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccineJohn L Perez, Judith Absalon, Johannes Beeslaar, et al.
The Pediatric Infectious Disease Journal|November 12, 2005
Immunogenicity and immunologic memory of meningococcal C conjugate vaccine in premature infantsClare L Collins, Jens U Ruggeberg, Gail Balfour, et al.
The Pediatric Infectious Disease Journal|May 1, 2007
High pneumococcal DNA loads are associated with mortality in Malawian children with invasive pneumococcal diseaseEnitan D Carrol, Malcolm Guiver, Standwell Nkhoma, et al.
Vaccine|October 31, 2006
Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infantsJens U Ruggeberg, Clare Collins, Paul Clarke, et al.
The Lancet. Infectious Diseases|September 10, 2022
Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studiesHelen S Marshall, Timo Vesikari, Peter C Richmond, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Vaccines|April 27, 2026
Immunogenicity and Safety of Extended Dosing Intervals for Pfizer Pentavalent MenABCWY Meningococcal Vaccination in Healthy Adolescents: Results from a Randomized, Phase 2b StudyJake C Jones, Mary D Tipton, Lefteris Zolotas, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 2, 2007
Chemokine responses are increased in HIV-infected Malawian children with invasive pneumococcal diseaseEnitan D Carrol, Limangeni A Mankhambo, Paul Balmer, et al.
Infectious Diseases and Therapy|January 30, 2025
A Phase 3B, Open-Label Study to Evaluate the Immunogenicity and Safety of the Quadrivalent Meningococcal Nimenrix<sup>®</sup> Vaccine When Given to Healthy Infants at 3 and 12 Months of AgeSusanna Koski, Federico Martinon-Torres, Mika Rämet, et al.
The Lancet. Infectious Diseases|August 14, 2023
Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trialJames Peterson, Daniel Drazan, Hanna Czajka, et al.
Critical Care (London, England)|May 25, 2010
The role of angiogenic factors in predicting clinical outcome in severe bacterial infection in Malawian childrenLimangeni A Mankhambo, Daniel L Banda, , et al.
Expert Review of Vaccines|June 9, 2018
From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccineJohn L Perez, Judith Absalon, Johannes Beeslaar, et al.
The Pediatric Infectious Disease Journal|November 12, 2005
Immunogenicity and immunologic memory of meningococcal C conjugate vaccine in premature infantsClare L Collins, Jens U Ruggeberg, Gail Balfour, et al.
The Pediatric Infectious Disease Journal|May 1, 2007
High pneumococcal DNA loads are associated with mortality in Malawian children with invasive pneumococcal diseaseEnitan D Carrol, Malcolm Guiver, Standwell Nkhoma, et al.
Vaccine|October 31, 2006
Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infantsJens U Ruggeberg, Clare Collins, Paul Clarke, et al.
The Lancet. Infectious Diseases|September 10, 2022
Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studiesHelen S Marshall, Timo Vesikari, Peter C Richmond, et al.
Pageof 8